Skip to main content

Table 4 Deterministic and probabilistic model projections of the number of advanced NSCLC patients receiving second- and third-line therapy in 2016 and in 2020 by country

From: The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions

Country Burden of illness measure Year of estimate
2016 2020
Deterministic Probabilistic Deterministic Probabilistic
Mean Mean Lower 95% CI Upper 95% CI Mean Mean Lower 95% CI Upper 95% CI
France Second LOT 11,600 11,700 10,500 12,800 13,900 13,900 12,500 15,400
Third LOT 3500 3500 3200 3800 4200 4200 3800 4500
Germany Second LOT 15,100 15,200 13,600 16,700 16,200 16,200 14,600 17,900
Third LOT 4900 4900 4500 5400 5200 5300 4800 5700
Italy Second LOT 13,500 13,600 11,900 15,600 15,100 15,600 13,500 18,200
Third LOT 2500 2500 2200 2800 2600 2700 2400 3100
Spain Second LOT 9400 9600 8400 11,100 11,000 11,800 9600 14,700
Third LOT 2100 2200 1900 2400 2500 2600 2200 3300
  1. Key: CI confidence interval, LOT line of therapy, NSCLC non-small cell lung cancer